After receiving his Ph.D. degree in Molecular Genetics in 1975 from the University of Leiden, the Netherlands, Herb started post-doctoral work in the laboratory of Prof. Herbert Boyer at UCSF. His work focused on cloning and expression of chemically synthesized DNA coding for the lac operator and somatostatin. The following year, when Boyer and Swanson founded Genentech, Herb was hired as the first scientist. Here he was involved in cloning and expression of genes coding for therapeutic proteins, including human insulin, human growth hormone and immunoglobulins (protected by the Cabilly I and II patents). In 1984 Herb joined Genencor, a spin-off from Genentech, as Vice-President of Research. Genencor applied recombinant DNA technology for the improvement and cost-effective manufacturing of industrial enzymes. In the 90s Herb co-founded three biotechnology companies including Eos, a functional genomics company, where he was the Chief Technology Officer. After Eos was acquired by Protein Design Labs in 2003, he joined the London-based Venture Capital Firm Abingworth (www.abingworth.com) as an advisor. Herb served on the Board of Directors for Prosensa and Profibrix, both in Leiden, and he consults for Crucell and Philips Healthcare Incubator, all in the Netherlands. He is an author on more than 50 peer-reviewed papers and an inventor on more than 30 US patents.
Jan van de Winkel
Professor Jan van de Winkel, Ph.D., is President and Chief Executive Officer of Genmab A/S, which he co-founded in Feb 1999. Genmab is a leading international biotechnology company focused on developing innovative antibody products for the potential treatment of cancer. Dr. van de Winkel has overseen the creation and development of a number of human antibodies for the treatment of cancer and other life-threatening and debilitating diseases. The first approved antibody, Arzerra, received regulatory authorization by the United States FDA [Oct 2009] and the European Medicines Agency [April 2010] for therapy of refractory chronic lymphocytic leukemia. Dr. van de Winkel is widely recognized as one of the leading scientists in the study of antibodies and their interaction with the immune system. Dr. van de Winkel has (co-) authored more than 300 scientific publications and has been responsible for over 40 patents and patent applications. He holds a Professorship of Immunotherapy at the University Medical Center Utrecht. Prior to joining Genmab, Dr. van de Winkel served as Vice President and Scientific Director of Medarex Europe. Professor van de Winkel is a scientific advisor to various international venture capital firms.
Professor Daan Crommelin, Ph.D., is presently vice-chair of the scientific advisory board of the European Innovative Medicines Initiative (IMI). He is also professor at the department of Pharmaceutics at Utrecht University, and adjunct professor at the University of Utah. Daan was Chief Scientific Officer of Octoplus, a company specialized in product formulations and drug delivery systems. He published over 260 articles and book chapters and is on the editorial board of 10 peer reviewed journals. He chaired the board of Pharmaceutical Sciences of the International Pharmaceutical Federation (FIP), was chair of the organizing committee of the Pharmaceuticals Sciences World Conference 2007 in Amsterdam and was president of the European Federation of Pharmaceutical Sciences (EUFEPS). Until recently he was scientific director of the Top Institute Pharma in Leiden. Professor Crommelin is a scientific advisor to various venture capital firms and pharmaceutical and biotechnology companies.
Peter van Brummelen
Professor Peter van Brummelen, M.D., Ph.D., is a member of the board of Directors IQ Corporation and IQ Therapeutics (The Netherlands). Before his retirement he was Executive Vice President of R&D at Yamanouchi Europe. Previously he was Vice President of clinical research and development and Chief Medical Officer at Solvay Pharmaceuticals. He also served as the worldwide Head of Clinical Pharmacology at Hoffmann-La Roche, Inc., based in Basel. Prior to joining the pharmaceutical industry, Professor van Brummelen held various academic positions at the University of Leiden and the University of Basel. He has (co-)authored more than 200 publications and book chapters. He received his M.D. and Ph.D. from the University of Leiden. Professor van Brummelen is an independent consultant to pharmaceutical companies and a scientific advisor to various international venture capital firms. Peter also gained extensive experience in the biotech sector as member of the Board of Directors of Basilea, BioXell, Diatos, and Movetis.
Staf Van Reet
Staf Van Reet, Ph.D., has a long track record in Pharma, among others as the Managing Director of Janssen Pharmaceutica N.V. and President of the Janssen Research Foundation, the worldwide research and development activities of the Janssen Group of companies. Additionally, Staf has solid experience in venture capital, having been responsible for corporate venturing in Europe as a Vice President of the Johnson & Johnson Development Corporation. Staf also gained extensive experience in the biotech sector as co-founder of Movetis and Chairman of its Board of Directors until the acquisition of the company by Shire. Currently, he is still active in various areas of the life sciences, among others as the founder and CEO of Viziphar Biosciences, as Chairman of the Board of Okapi Sciences and a Board member of Thrombogenics, Biocartis and TheraSolve, and of the VIB, the Flemish Institute of Biotechnology.
Kathleen A. Marshall
Ms. Marshall holds a BA from Amherst College and an MS in Regulatory Affairs from Northeastern University. She is an experienced senior executive skilled in clinical research, market development and commercialization of new medical technologies. During her career in medical device start-ups, she has established a proven track record in conducting international clinical studies, building global markets, branding emerging technologies and leading start-up ventures. Kathleen began her medical device career in the early days of interventional cardiology start-ups, at Advanced Cardiovascular Systems (ACS—later Guidant/Abbott) and, subsequently, the Senior Management team of Cardiovascular Imaging Systems (CVIS—later acquired by Boston Scientific). She was a founding member of Cardiothoracic Systems, Inc. (CTSI) and led the clinical development of the company resulting in an initial public offering of $86 million in 1996. Subsequently she joined Embol-X (later acquired by Edwards Lifesciences) as Vice President of Marketing during which she managed European clinical studies. She has successfully established and managed teams that have created lasting clinical value and financial returns. In 2003, after nearly twenty years as a significant strategic contributor to the overall success of multiple medical device start-up companies, Ms. Marshall created MAXIS Medical, a clinical market development company, providing services in strategic clinical research, regulatory affairs and market development to emerging medical device companies. Ms. Marshall holds dual citizenship in the USA and Ireland.